IND as a KP inhibitor reverses the effects of TRP depletion in the tumor microenvironment, which results in the reactivation of MAP4K3 and subsequent activation of mTORC1 activity, together with the inactivation of GCN2 kinase in T helper cells [26]. The gene discussed is MAP4K3; the disease is neoplasm.